EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Novel Approach for Assessing Outcomes of Type 1 Diabetes Prevention Trials Over a Fixed Time Interval

Emily K Sims iD, William E Russell, David Cuthbertson, Jay S Skyler, Laura M Jacobsen, Heba M Ismail iD, Maria J Redondo, Brandon M Nathan, Alice L J Carr, Peter N Taylor, Colin M Dayan, Alfonso Galderisi und 2 weitere

Diabetes · 2025

DOI: 10.2337/db25-0310 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, 2025. Verfasst von Emily K Sims und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Diabetes and Metabolic Diseases, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Abatacept. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Doris Duke Charitable Foundation, NCRR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We evaluated whether a binary metabolic end point for change (Δ) from baseline to 1-year postrandomization could be useful in type 1 diabetes (T1D) prevention trials. Using 2-h oral glucose tolerance testing data from the stage 1 participants in the recent abatacept prevention trial and similar participants in the observational TrialNet Pathway to Prevention (PTP) study, we assessed Δmetabolic measures, plotted glucose and C-peptide response curves, and categorized vectors for Δ from baseline to 1 year as metabolic treatment failure versus success. Analyses were validated using the teplizumab prevention study. PTP participants with Δglucose >0 and ΔC-peptide <0 from baseline to 1 year were at substantially higher risk for stage 3 T1D than those with Δglucose <0 and ΔC-peptide >0 (P < 0.0001). Based on this, we compared placebo versus treatment groups in both trials for failure (Δglucose >0 with ΔC-peptide <0) versus success (Δglucose <0 with ΔC-peptide >0) after 1 year. Using this end point, a favorable metabolic impact of abatacept was found after 12 months of treatment. An analytic approach using a binary metabolic end point of failure versus success at a fixed time interval appears to detect treatment effects at least as well as standard primary end points with shorter follow-up. Article Highlights Challenges in time to event type 1 diabetes (T1D) prevention trial design can yield negative results even for treatments that may actually improve disease pathology. We evaluated whether a binary metabolic end point for 12-month change from baseline to 1 year postrandomization could be useful in T1D prevention trials. This approach detected treatment effects at least as well as standard primary end points with shorter follow-up. Fixed interval metabolic end points should be used in combination with traditional T1D end points to better understand treatment effects of preventive agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1AbataceptHumansFemaleMaleC-PeptideBlood GlucoseGlucose Tolerance TestTreatment OutcomeAdolescentAntibodies, Monoclonal, HumanizedAdultChild

Substanzen

AbataceptC-PeptideBlood GlucoseteplizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Center for Diabetes and Metabolic Diseases, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN.
  • Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN.
  • Departments of Pediatrics and Cell and Developmental Biology, Vanderbilt University, Nashville, TN.
  • Health Informatics Institute, Morsani College of Medicine, University of South Florida, Tampa, FL.
  • University of Miami, Coral Gables, FL.
  • Departments of Pediatrics and Pathology, University of Florida College of Medicine, Gainesville, FL.

ORCID-Profile: Emily K Sims, Heba M Ismail

Förderung

  • NIDDK NIH HHS
  • Doris Duke Charitable Foundation
  • NCRR NIH HHS
  • SRA
  • Alberta Diabetes Institute
  • JDRF
  • NIH HHS
  • National Institutes of Health (NIH)

Zitieren

APA

Sims, E. K., Russell, W. E., Cuthbertson, D., Skyler, J. S., Jacobsen, L. M., Ismail, H. M., Redondo, M. J., Nathan, B. M., Carr, A. L. J., Taylor, P. N., Dayan, C. M., Galderisi, A., Herold, K. C., & Sosenko, J. M. (2025). Novel Approach for Assessing Outcomes of Type 1 Diabetes Prevention Trials Over a Fixed Time Interval. Diabetes. https://doi.org/10.2337/db25-0310

Vancouver

Sims EK, Russell WE, Cuthbertson D, Skyler JS, Jacobsen LM, Ismail HM, et al. Novel Approach for Assessing Outcomes of Type 1 Diabetes Prevention Trials Over a Fixed Time Interval. Diabetes. 2025. doi:10.2337/db25-0310

BibTeX
@article{Sims2025,
  author = {Sims, Emily K and Russell, William E and Cuthbertson, David and Skyler, Jay S and Jacobsen, Laura M and Ismail, Heba M and Redondo, Maria J and Nathan, Brandon M and Carr, Alice L J and Taylor, Peter N and Dayan, Colin M and Galderisi, Alfonso and Herold, Kevan C and Sosenko, Jay M},
  title = {Novel Approach for Assessing Outcomes of Type 1 Diabetes Prevention Trials Over a Fixed Time Interval},
  journal = {Diabetes},
  year = {2025},
  doi = {10.2337/db25-0310}
}
Kostenlos starten →